Proffitt & Goodson’s Moderna MRNA Stock Holding History

Proffitt & Goodson’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7K	Hold	100	–	–	﹤0.01%	261
2026 Q1	$5.08K	Buy	+100	New	+$4.67K	﹤0.01%	256
2025 Q4	–	Sell	-150	Closed	-$3.88K	–	388
2025 Q3	$3.88K	Hold	150	–	–	﹤0.01%	327
2025 Q2	$4.14K	Hold	150	–	–	﹤0.01%	237
2025 Q1	$4.25K	Buy	+150	New	+$5.32K	﹤0.01%	228
2024 Q4	–	Sell	-50	Closed	-$3.34K	–	290
2024 Q3	$3.34K	Hold	50	–	–	﹤0.01%	252
2024 Q2	$5.94K	Hold	50	–	–	﹤0.01%	240
2024 Q1	$5.33K	Hold	50	–	–	﹤0.01%	208
2023 Q4	$4.97K	Hold	50	–	–	﹤0.01%	201
2023 Q3	$5.17K	Hold	50	–	–	﹤0.01%	202
2023 Q2	$6.08K	Hold	50	–	–	﹤0.01%	196
2023 Q1	$7.68K	Hold	50	–	–	﹤0.01%	197
2022 Q4	$8.98K	Buy	+50	New	+$8.18K	﹤0.01%	195

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Proffitt & Goodson's MRNA Position: Q2 2026 in Review

Proffitt & Goodson held its Moderna (MRNA) position steady in Q2 2026 at 100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #261.

Proffitt & Goodson first reported a position in MRNA in Q4 2022 and has held it in 13 quarters since. The position peaked at $8.98K in Q4 2022. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Proffitt & Goodson held 100 shares of Moderna worth $7K as of Q2 2026.
Proffitt & Goodson left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Proffitt & Goodson's portfolio in Q2 2026, its #261 holding.
Proffitt & Goodson first reported a position in Moderna in Q4 2022 and has held it in 13 quarters since.
Proffitt & Goodson's Moderna position peaked at $8.98K in Q4 2022.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Proffitt & Goodson's 13F filing for Q2 2026, filed 22 Jul 2026.